Light RFP
Federal · SAM.gov · Maryland

NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAM

Due Sep 21, 2026·55 days left·General ConstructionView official posting ↗
Issuing agency
Department of Health and Human Services
Method
Solicitation
Category
NAICS 54171
PIN
75N98026R00109
Location
Maryland
Posted
Jul 10, 2026
Takeaways by LightRFP AI

Generate a quick AI overview of this bid, pulled from its details and the attached documents.

Description

The National Cancer Institute (NCI) invites small business concerns to submit research proposals under this Phase I Small Business Innovation Research (SBIR) contract solicitation. Firms with the capability to conduct research and development (R&D) in the health-related topic areas referred to below and described more fully in Section 11.0, and to commercialize the results of that R&D, are encouraged to participate.

The topic areas that are being sought under this solicitation are:

  • Topic 1: Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.

For this solicitation rare cancers with a 5-year survival rate of less than 50% are encouraged**.**

  • Topic 2: Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.

For this solicitation, rare cancers with a 5-year survival rate of less than 50% are encouraged.

The National Cancer Institute is soliciting proposals from small business concerns who are looking for an opportunity to perform a few key activities to demonstrate proof-of-concept and feasibility of untested but potentially transformative, game-changing research and development (R&D) technologies to help cancer patients, providers and caregivers, in conjunction with Small Business Innovation Research (SBIR) program objectives. The NCI has established a high-risk, high-reward SBIR “Innovative Concept Award” Program for this purpose.

Preliminary data is not required; however, the ideas should have sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data.

Note: Non-exempt Human subjects research will not be supported under this solicitation.

Phase I Concept Award contractors will be informed of the opportunity to apply for Phase II. Only one Phase II award may result from a single Phase I SBIR contract. The United States Department of Health and Human Services (HHS) is not obligated to make any awards under this solicitation. All awards are subject to the availability of funds. HHS is not responsible for any monies expended by the offeror before award of any contract.

Documents3
Attachment_1-Technical_Proposal_Form-NCI_SBIR_FY25_Concept_Award_Solicitation (1).pdfPDF
Amendment 0001 - 75N98026R00109.pdfPDF
FY27 NCI SBIR Concept Solicitation Phase I -75N98026R00109.pdfPDF

Contact

Name
Kathleen Sears
Address
MD 20892
Full source recordfrom SAM.gov
Type
Solicitation
Title
NATIONAL CANCER INSTITUTE (NCI) SMALL BUSINESS INNOVATION RESEARCH (SBIR) INNOVATIVE CONCEPT PHASE I AWARD PROGRAM
Active
Yes
Base Type
Solicitation
Notice Id
8fbf26c5215646f582bf9fe4b4f00fca
Naics Code
54171
Department
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Posted Date
Jul 10, 2026
Categorized By
llm-nc
Office Address
State
MD
Zipcode
20892
Country Code
USA
Point Of Contact
Type
primary
Email
ncioasbir@mail.nih.gov
Full Name
Kathleen Sears
Description Text
The National Cancer Institute (NCI) invites small business concerns to submit research proposals under this Phase I Small Business Innovation Research (SBIR) contract solicitation. Firms with the capability to conduct research and development (R&D) in the health-related topic areas referred to below and described more fully in Section 11.0, and to commercialize the results of that R&D, are encouraged to participate. The topic areas that are being sought under this solicitation are: - **Topic 1:** Development of therapeutic or preventative technologies for treatment or prevention of **Pediatric Cancers and/or Rare Cancers.** For this solicitation rare cancers with a 5-year survival rate of less than 50% are encouraged**.** - **Topic 2:** Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of **Pediatric Cancers and/or Rare Cancers.** For this solicitation, rare cancers with a 5-year survival rate of less than 50% are encouraged. The National Cancer Institute is soliciting proposals from small business concerns who are looking for an opportunity to perform a few key activities to demonstrate proof-of-concept and feasibility of untested but potentially transformative, game-changing research and development (R&D) technologies to help cancer patients, providers and caregivers, in conjunction with Small Business Innovation Research (SBIR) program objectives. The NCI has established a high-risk, high-reward SBIR “Innovative Concept Award” Program for this purpose. Preliminary data is not required; however, the ideas should have sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. **Note: Non-exempt Human subjects research will not be supported under this solicitation.** Phase I Concept Award contractors will be informed of the opportunity to apply for Phase II. Only one Phase II award may result from a single Phase I SBIR contract. The United States Department of Health and Human Services (HHS) is not obligated to make any awards under this solicitation. All awards are subject to the availability of funds. HHS is not responsible for any monies expended by the offeror before award of any contract.
Response Dead Line
Sep 21, 2026
Full Parent Path Name
DEPARTMENT OF HEALTH AND HUMAN SERVICES.NATIONAL INSTITUTES OF HEALTH.NIH NCI
Place Of Performance
Country
Code
USA
Name
UNITED STATES
Solicitation Number
75N98026R00109

Source: SAM.gov (notice 8fbf26c5215646f582bf9fe4b4f00fca), retrieved via the SAM.gov Get Opportunities API. View the official posting — always confirm requirements and deadlines with the issuing agency.